These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17491025)

  • 1. Rescue of a nephrogenic diabetes insipidus-causing vasopressin V2 receptor mutant by cell-penetrating peptides.
    Oueslati M; Hermosilla R; Schönenberger E; Oorschot V; Beyermann M; Wiesner B; Schmidt A; Klumperman J; Rosenthal W; Schülein R
    J Biol Chem; 2007 Jul; 282(28):20676-85. PubMed ID: 17491025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-causing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway.
    Hermosilla R; Oueslati M; Donalies U; Schönenberger E; Krause E; Oksche A; Rosenthal W; Schülein R
    Traffic; 2004 Dec; 5(12):993-1005. PubMed ID: 15522100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
    Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
    Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism.
    Robben JH; Sze M; Knoers NV; Deen PM
    Mol Biol Cell; 2006 Jan; 17(1):379-86. PubMed ID: 16267275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.
    Robben JH; Kortenoeven ML; Sze M; Yae C; Milligan G; Oorschot VM; Klumperman J; Knoers NV; Deen PM
    Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12195-200. PubMed ID: 19587238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical validation and optimization of pharmacoperones targeting vasopressin type 2 receptor mutant.
    Janovick JA; Spicer TP; Bannister TD; Smith E; Ganapathy V; Scampavia L
    Biochem J; 2018 Sep; 475(18):2941-2953. PubMed ID: 30068530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus.
    Morello JP; Salahpour A; Petäjä-Repo UE; Laperrière A; Lonergan M; Arthus MF; Nabi IR; Bichet DG; Bouvier M
    Biochemistry; 2001 Jun; 40(23):6766-75. PubMed ID: 11389590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
    Robben JH; Sze M; Knoers NV; Deen PM
    Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide.
    Schoneberg T; Yun J; Wenkert D; Wess J
    EMBO J; 1996 Mar; 15(6):1283-91. PubMed ID: 8635461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies.
    Mouillac B; Mendre C
    Pharmacol Res; 2014 May; 83():74-8. PubMed ID: 24239889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
    Prosperi F; Suzumoto Y; Marzuillo P; Costanzo V; Jelen S; Iervolino A; Guarino S; La Manna A; Miraglia Del Giudice E; Perna AF; Zacchia M; Cordat E; Capasso G; Trepiccione F
    Sci Rep; 2020 Oct; 10(1):16383. PubMed ID: 33009446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
    Takahashi K; Makita N; Manaka K; Hisano M; Akioka Y; Miura K; Takubo N; Iida A; Ueda N; Hashimoto M; Fujita T; Igarashi T; Sekine T; Iiri T
    J Biol Chem; 2012 Jan; 287(3):2099-106. PubMed ID: 22144672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
    Makita N; Sato T; Yajima-Shoji Y; Sato J; Manaka K; Eda-Hashimoto M; Ootaki M; Matsumoto N; Nangaku M; Iiri T
    J Biol Chem; 2016 Oct; 291(43):22460-22471. PubMed ID: 27601473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
    Robben JH; Deen PM
    BioDrugs; 2007; 21(3):157-66. PubMed ID: 17516711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
    Los EL; Deen PM; Robben JH
    J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Misfolded vasopressin V2 receptors caused by extracellular point mutations entail congential nephrogenic diabetes insipidus.
    Postina R; Ufer E; Pfeiffer R; Knoers NV; Fahrenholz F
    Mol Cell Endocrinol; 2000 Jun; 164(1-2):31-9. PubMed ID: 11026555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
    Robben JH; Knoers NV; Deen PM
    Am J Physiol Renal Physiol; 2005 Aug; 289(2):F265-72. PubMed ID: 16006591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
    Oksche A; Schülein R; Rutz C; Liebenhoff U; Dickson J; Müller H; Birnbaumer M; Rosenthal W
    Mol Pharmacol; 1996 Oct; 50(4):820-8. PubMed ID: 8863826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors.
    Wüller S; Wiesner B; Löffler A; Furkert J; Krause G; Hermosilla R; Schaefer M; Schülein R; Rosenthal W; Oksche A
    J Biol Chem; 2004 Nov; 279(45):47254-63. PubMed ID: 15319430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Derlin-1 and p97/valosin-containing protein mediate the endoplasmic reticulum-associated degradation of human V2 vasopressin receptors.
    Schwieger I; Lautz K; Krause E; Rosenthal W; Wiesner B; Hermosilla R
    Mol Pharmacol; 2008 Mar; 73(3):697-708. PubMed ID: 18048502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.